Ressources
Actualités
-
Augmentation de la capacité de production de Plomb-212 pour le développement de traitements contre le cancer
-
Orano Med étend ses capacités de production en France et aux Etats-Unis
-
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors
Evènements
EANM - European Association of Nuclear Medicine 2019 Congress
12-16 octobre 2019 - Barcelone, Espagne
En savoir plus
Publications scientifiques (en anglais)
Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
VCAM-1 targeted alpha-particle therapy for early brain metastases
212Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Safety and Outcome Measures of First-in-Human Intraperitoneal Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
